Clinical Trials 2015 Practical Session 2. Exercise I Normally Distributed Response Data H 0 :  = 0 H a :  =  a > 0 n=? α=0.05 (two-sided) β=0.20 

Slides:



Advertisements
Similar presentations
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Advertisements

**************** GCRC Research-Skills Workshop October 26, 2007 William D. Dupont Department of Biostatistics **************** How to do Power & Sample.
Choosing Endpoints and Sample size considerations
Targeted (Enrichment) Design. Prospective Co-Development of Drugs and Companion Diagnostics 1. Develop a completely specified genomic classifier of the.
1 Financial Mathematics Clicker review session, Midterm 01.
1 Financial Mathematics Clicker review session, Final.
Financial Mathematics Clicker review session, Midterm 01 1.
Assuming normally distributed data! Naïve Bayes Classifier.
1 Financial Mathematics Clicker review session, Midterm 01.
1 Equivalence and Bioequivalence: Frequentist and Bayesian views on sample size Mike Campbell ScHARR CHEBS FOCUS fortnight 1/04/03.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
CSE 221: Probabilistic Analysis of Computer Systems Topics covered: Exponential distribution Reliability and failure rate (Sec )
2. Random variables  Introduction  Distribution of a random variable  Distribution function properties  Discrete random variables  Point mass  Discrete.
RAMPART Statistical Analysis Plan Valerie Durkalski NETT Statistical and Data Management Center Department of Biostatistics, Bioinformatics & Epidemiology.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Phase II Design Strategies Sally Hunsberger Ovarian Cancer Clinical Trials Planning Meeting May 29, 2009.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Sample Size Determination Ziad Taib March 7, 2014.
Power and Sample Size Part II Elizabeth Garrett-Mayer, PhD Assistant Professor of Oncology & Biostatistics.
Find the mean & St. Dev for each. MeanSt. Dev X83 Y124.
Lesson 12-1 Algebra Check Skills You’ll Need 12-4
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Lecture 3 Survival analysis.
The paired sample experiment The paired t test. Frequently one is interested in comparing the effects of two treatments (drugs, etc…) on a response variable.
CI - 1 Cure Rate Models and Adjuvant Trial Design for ECOG Melanoma Studies in the Past, Present, and Future Joseph Ibrahim, PhD Harvard School of Public.
Statistical Power and Sample Size Calculations Drug Development Statistics & Data Management July 2014 Cathryn Lewis Professor of Genetic Epidemiology.
Statistics for Engineer Week II and Week III: Random Variables and Probability Distribution.
Confidence Intervals Elizabeth Garrett-Mayer
#1 STATISTICS 542 Introduction to Clinical Trials SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
Optimal cost-effective Go-No Go decisions Cong Chen*, Ph.D. Robert A. Beckman, M.D. *Director, Merck & Co., Inc. EFSPI, Basel, June 2010.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.
Chapter 12 Probability. Chapter 12 The probability of an occurrence is written as P(A) and is equal to.
Survival Analysis, Type I and Type II Error, Sample Size and Positive Predictive Value Larry Rubinstein, PhD Biometric Research Branch, NCI International.
통계적 추론 (Statistical Inference) 삼성생명과학연구소 통계지원팀 김선우 1.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
1 Central Limit Theorem The theorem states that the sum of a large number of independent observations from the same distribution has, under certain general.
Binomial Probability. Features of a Binomial Experiment 1. There are a fixed number of trials. We denote this number by the letter n.
6.2 BINOMIAL PROBABILITIES.  Features  Fixed number of trials (n)  Trials are independent and repeated under identical conditions  Each trial has.
 An exposure-response (E-R) analysis in oncology aims at describing the relationship between drug exposure and survival and in addition aims at comparing.
Results from a Randomized Phase III Trial of Decitabine versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed.
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
1 Underlying population distribution is continuous. No other assumptions. Data need not be quantitative, but may be categorical or rank data. Very quick.
Normal Approximation to the Binomial Distribution.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
ΟΡΓΑΝΩΣΗ ΚΑΙ ΔΙΟΙΚΗΣΗ ΕΠΙΧΕΙΡΗΣΕΩΝ 3 Ο ΜΑΘΗΜΑ. ΟΙ ΜΕΓΑΛΕΣ ΕΠΙΧΕΙΡΗΣΕΙΣ Η δημιουργία μεγάλων επιχειρήσεων είναι ένα από τα χαρακτηριστικά του 20 ου αιώνα.
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Slamon D et al. SABCS 2009;Abstract 62.
Table 1. Patient Characteristics
Impact of censoring on the statistical methods for handling non-proportional hazards in Immuno-Oncology studies Yifan Huang, Luping Zhao, Jiabu Ye, and.
Discrete Probability Distributions
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Chapter 6 Minitab Recipe Cards
Normal Density Curve. Normal Density Curve 68 % 95 % 99.7 %
EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.
ОПЕРАТИВНА ПРОГРАМА “ИНОВАЦИИ И КОНКУРЕНТОСПОСОБНОСТ“ „Подобряване на производствения капацитет в МСП“
A B Yeom Supplementary Fig.2
THE NORMAL DISTRIBUTION AND THE 68–95–99.7% RULE
If the question asks: “Find the probability if...”
Solving Equations 3x+7 –7 13 –7 =.
Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios
ARISE Trial Aggressive Reduction of Inflammation Stops Events
HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.
A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.
Sample Size and Power Part II
U A B II III I IV 94.
Presentation transcript:

Clinical Trials 2015 Practical Session 2

Exercise I Normally Distributed Response Data H 0 :  = 0 H a :  =  a > 0 n=? α=0.05 (two-sided) β=0.20  a /  = 0.25

Exercise II Binary (binomial) response data EAST works in a similar way for binary response data, except that you now enter the probability of an event for the control and then either the probability for the treatment group or the difference in probabilities.

Exercise III Survival Data H 0 : HR = 1 H a : HR <1 (new treatment decreases Hazard) n=? Assume median survival in the control arm= 6 months Assume HR=1/2 α=0.05 (two-sided) β=0.20 Accrual rate=30 patients / month

Exercise IV Noninferiority Trial– Binomial Response H 0 : p T – p S >  0 (the new treatment is considered inferior) H A : p T – p S <  0 (the new treatment is considered non-inferior) – α=0.025 (one-sided) – β=0.10 – p S =0.10 (Probability of event in the control group) –  0 =0.06